Clinical Trials Directory

Trials / Completed

CompletedNCT04825886

Efficacy and Safety of ZotaRolimus-Eluting Coronary Stent System In Patients With Long Coronary Artery Disease

Evaluation of Effectiveness and Safety of ZotaRolimus-Eluting Coronary Stent System In Patients With Long Coronary Artery Disease; A Multicenter, Prospective, Observational Registry Study

Status
Completed
Phase
Study type
Observational
Enrollment
2,000 (actual)
Sponsor
Chonnam National University Hospital · Academic / Other
Sex
All
Age
19 Years
Healthy volunteers
Not accepted

Summary

This study is to evaluation the efficacy and safety of Zotarolimus-Eluting Stent in patients with long coronary artery disease of 25 mm or longer.

Detailed description

Study objectives: From this observational prospective study, the efficacy and safety of Zotarolimus-Eluting Stent in patients with coronary artery disease longer than 25mm is planned to be investigated. Background: Long coronary artery lesions are observed in 20% of all coronary interventions, and are associated with poor clinical outcomes. Zotarolimus-Eluting Stents are a new type of stent that combines the advantages of an Endeavour Resolute stent (drug eluting stent) and Integrity stent (bare metal stent). In other words, BioLinx polymer is used which is an advantage of Endeavour Resolute stent to secure clinical efficiency through stable drug release while ensuring flexibility and excellent deliverability, which is the advantage of Integrity stent. To date, there are only few studies to evaluate the efficacy and safety of Zotarolimus-Eluting Stent in the treatment of coronary artery disease. Therefore, the investigators planned to carry out a multicenter, prospective observational study to evaluated the efficacy and safety of Zotarolimus-Eluting Stent in patients with long coronary artery disease of 25 mm or longer.

Conditions

Interventions

TypeNameDescription
DEVICEZotarolimus-Eluting StentPercutaneous coronary intervention using zotarolimus-eluting stent

Timeline

Start date
2017-12-28
Primary completion
2021-03-18
Completion
2022-03-18
First posted
2021-04-01
Last updated
2024-02-06

Locations

20 sites across 1 country: South Korea

Source: ClinicalTrials.gov record NCT04825886. Inclusion in this directory is not an endorsement.